ViroStatics is a privately held small pharmaceutical company dedicated to the discovery and the development of novel compounds for a multifaceted treatment of cancers and viral diseases, focusing on novel, selective, host cell kinase targeted inhibitors and inherently hindering the oncogene Myc.
The Team and Advisors combines scientific, business, legal, and technology expertise, spanning from translational science through preclinical and clinical drug development.
ViroStatics intends to license its compounds at the preclinical stage, with a patent protection to be extended until 2043.
Clinical Candidate Myrtleciclib
With a unique mechanism of action (blocking Myc ensuring selective, non-competitive CDK9/6/4 inhibition) Myrtleciclib exerts anti-proliferative activity against a broad spectrum of cancers, superior to comparators, and induces apoptosis and cell death, selectively on cancer cells. Learn more
ViroStatics is an independent contract testing laboratory specialized in the analysis of respiratory viruses such as SARS-CoV-2 and flu.
ViroStatics has developed a bioaerosol system in order to test nebulised drug treatments, inhalers, disinfectants or devices for virucidal activity in a state-of-the-art Biosafety Level 3 facility, according to the US CDC guidelines to identify countermeasures to minimise risk of infection.